All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The ability to predict therapeutic response is essential for improving the care of patients with acute myeloid leukemia (AML). M.Luskin et al. developed a methylation-based risk score (M-score) for AML using random forest classification and demonstrated the association between M-score and overall survival (OS) on a limited cohort of AML patients.
For this current study M.Luskin et al. of UPENN, investigated whether the M-score could independently predict clinical outcome in 166 patients from UPENN with de novo AML treated with intensive induction chemotherapy controlling for other prognostic markers. Their findings were published in JCI Insight in June 2016.
In summary, this study has demonstrated some promising results regarding the robustness of the M-score as a prognostic tool. As correlations between the median M-score and OS and the median M-score and CR were observed.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox